RxDoctor Payments Data

Samuel Foster, MD

Cardiovascular Disease · Prince Frederick, MDNPI 1780665984

Payments from drug & device makers

$1,273in general payments, 2019–2025

Across 26 payments — averaging $48.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$410
  • Medtronic$257
  • AstraZeneca$217
  • Novartis$103
  • Regeneron Healthcare Solutions, Inc.$84
  • Amgen$81
  • plus $121 from 4 others

What the payments were for

  • Food & beverage$1,08085%
  • Education$19315%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,273 in reported general payments places this provider in the 40th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$600,603
Medicare patients
1,313
Services billed
6,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban268$392,414
XareltoRivaroxaban129$181,192
Bosentan12$112,934
EntrestoSacubitril/Valsartan41$61,959
FarxigaDapagliflozin Propanediol34$41,644
MultaqDronedarone Hcl16$34,335
Repatha SyringeEvolocumab38$31,688
Repatha SureclickEvolocumab17$26,295
Praluent PenAlirocumab15$12,212
CorlanorIvabradine Hcl14$9,878
Sildenafil Citrate13$8,385
Metoprolol Succinate481$7,979
Rosuvastatin Calcium252$6,034
Eplerenone67$5,888
Dabigatran EtexilateDabigatran Etexilate Mesylate17$5,095

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$392,414268 claims
Johnson & JohnsonXarelto$23$181,192129 claims
NovartisEntresto$103$61,95941 claims
AstraZenecaFarxiga$217$41,64434 claims
AmgenCorlanor$81$9,87814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Prince Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →